Nicotinamide Riboside (NR/Niagen).

The body turns NR into NAD+, and the leftover nicotinamide is cleared by tagging it with a methyl group borrowed from the body's methyl pool. Betaine donates methyl groups, so it helps keep that pool topped up while NR raises NAD+ turnover.

Inside mitochondria, NAD+ from NR carries electrons into the respiratory chain as NADH, and CoQ10 picks those electrons up at the very next step. Because they act at adjacent stations of the same chain, both support normal cellular energy production.

Sirtuins, a family of enzymes that help regulate normal cell metabolism, run on NAD+ and use it up as they work. NR restocks the NAD+ these enzymes draw down, while resveratrol is studied as a compound that nudges the same sirtuins toward more activity.

NAD+ is steadily broken down in the body by the enzyme CD38, and apigenin is a flavonoid studied for slowing that enzyme. Pairing it with NR works from two sides of the same balance, adding NAD+ while easing the rate at which it is consumed.

NR is converted through NMN into NAD by the salvage route, one step from the coenzyme. It is the delivery form for that pool.

Clearing surplus nicotinamide spends a methyl group from S-adenosylmethionine. Raising precursor intake raises that methyl demand.

Methylfolate drives homocysteine remethylation, which regenerates the methyl donor pool that nicotinamide disposal draws down. It supports the same cycle by the folate arm.

Methionine synthase is a B12 enzyme, and without it the folate methyl group cannot reach homocysteine. Methyl turnover behind nicotinamide clearance depends on it.

Sirtuins use NAD as a co-substrate, so a sirtuin-side polyphenol is paired with the NAD-side precursor. The two sit on either side of one enzyme reaction.

NR becomes NMN before becoming NAD, so both act on one pathway at adjacent steps. Stacking them raises the same pool rather than two.

Nicotinamide enters NAD salvage a step earlier through NAMPT and also acts as a product inhibitor of sirtuins. The forms overlap in output, so one is normally chosen over the other.

Tryptophan builds NAD through the kynurenine route rather than salvage. The two routes converge on one coenzyme pool.

NAD is built two ways: salvaged from precursors such as nicotinamide riboside, or made de novo from tryptophan. The de novo arm runs through kynureninase, a pyridoxal-5-phosphate enzyme, so B6 status governs how much NAD the body can assemble without a precursor. Pairing the two covers both arms of the same pool. This is cofactor biochemistry rather than a tested combination.

Riboflavin becomes FAD and FMN. FAD drives kynurenine 3-monooxygenase in the de novo NAD pathway, and FMN accepts electrons from NADH at complex I. Raising the NAD pool without the flavin cofactors that turn NADH back over addresses only half of the cycle. Mechanistic, not an outcome claim.

Nicotinamide riboside is phosphorylated to NMN, then NMN adenylyltransferase adds an adenylyl group from ATP to finish NAD. That step, and the NAD kinase step that makes NADP, both run on magnesium-ATP. Magnesium is part of the machinery that converts the precursor into the finished dinucleotide.

Nicotinamide that is not salvaged back into NAD gets methylated by NNMT, and every methyl group comes from S-adenosylmethionine. Choline, via betaine, is one of the routes that regenerates methionine and keeps that pool supplied. Higher precursor intakes therefore sit downstream of methyl-donor status. The relationship is biochemical bookkeeping, not a demonstrated clinical effect.

CD38 hydrolyses NAD and NMN and accounts for a large share of NAD turnover in tissue. Quercetin and structurally similar flavones inhibit it in enzyme and cell work. Combining a precursor that fills the pool with an inhibitor that slows its drain is a coherent pairing on mechanism. Human combination outcome data is not what this rests on.

NADP is made from NAD, and its reduced form NADPH is the reducing currency that glutathione reductase uses to recycle oxidised glutathione. A precursor that supports the NAD pool therefore sits upstream of glutathione recycling capacity. Reduced glutathione status is a marker of redox handling, not an outcome in itself.

N-acetylcysteine supplies the cysteine that limits glutathione synthesis, while the NAD pool supplies, via NADP, the NADPH that keeps glutathione reduced. One provides substrate and the other provides reducing power for the same system. The pairing is mechanistic and is not a claim about any measured joint result.

Alpha-lipoic acid is the cofactor of the pyruvate and alpha-ketoglutarate dehydrogenase complexes, whose final step hands electrons to NAD through dihydrolipoamide dehydrogenase. The two sit on the same oxidative decarboxylation step, one as the swinging arm and one as the electron acceptor. Read it as mechanistic rather than clinical.

The first committed step from tryptophan toward NAD is run by heme-containing dioxygenases, so iron status shapes de novo NAD synthesis. A ribosyl precursor bypasses that step entirely and enters through the salvage route. The two feed one pool by different doors, which is why they are worth reading together.

Nicotinamide riboside already carries its ribose, which is why it enters the pathway one phosphorylation from NMN. Free nicotinamide instead needs phosphoribosyl pyrophosphate, drawn from the pentose phosphate pathway. Ribose availability is the common denominator behind both routes. The link is structural chemistry rather than a combination study.

A 2026 review sets nicotinamide riboside and berberine against the same mitochondrial handling pathways, with berberine acting largely through AMPK signalling and the riboside through NAD availability. AMPK and NAD-dependent sirtuin signalling intersect, which is the review authors' rationale for looking at them together. This is a review-level mechanistic overlap, not a trial of the pair.

Creatine buffers ATP through the phosphocreatine shuttle, while the NAD pool sets how fast substrate oxidation can regenerate ATP. The two act at different points of the same energy economy in skeletal muscle. Formulators combine them for that reason. No joint outcome is asserted here.